Shionogi & Co., Ltd. will acquire US biotech venture IntraBio for $2 billion, aiming to strengthen its rare disease drug business. It will pursue its growth strategy by making IntraBio a wholly owned subsidiary.
Shionogi & Co., Ltd. announced that it would acquire US biotech venture IntraBio. The acquisition is valued at $2 billion, and Shionogi plans to acquire all outstanding shares and make IntraBio a wholly owned subsidiary. The aim is to incorporate IntraBio's rare disease drug development capabilities and drive business growth.
IntraBio was established in 2015 and specializes in the research and development of rare disease drugs for neurological conditions. Its revenue for the fiscal year ended December 2025 was reported as $67.86 million.
Shionogi & Co., Ltd. has been working to strengthen its rare disease drug business as a priority area outside infectious diseases, and began global sales of a treatment for amyotrophic lateral sclerosis (ALS) in April this year.